Lung cancer begins in the lungs, and is basically of two types, known as, small cell lung cancer and non-small cell lung cancer. Lung cancer is largely seen in individuals with smoking habits. It is also considered to be the second leading cause of deaths in the United States. By conducting diagnostic tests within time, it is possible to effectively treat the cancer and also accordingly control the spreading of tumor.
Increasing prevalence of lung cancer as well as increase in smoking habits among youth is expected to fuel the growth of the lung cancer diagnosis market during the forecast period. Moreover, the introduction of new and better products by manufacturers is anticipated to offer growth opportunities to the companies in the market.

The "Global Lung Cancer Diagnosis Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by test, technology and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading lung cancer diagnosis market players and offers key trends and opportunities in the market.

The global lung cancer diagnosis market is segmented on the basis of test and technology. Based on test, the market is segmented as, sputum cytology, biopsy, imaging, molecular test, and other tests. On the basis of technology, the lung cancer diagnosis market is classified as, fluorescent in situ hybridization (FISH), immunohistochemical (IHC), and other technologies.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global lung cancer diagnosis market based on test and technology. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lung cancer diagnosis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

North America is expected to contribute to the largest share in the lung cancer diagnosis market in the coming years, owing to rising prevalence of lung cancer cases in the region during the recent years. Asia Pacific is expected to witness significant growth in the market during the forecast period, due to changing lifestyle trends and increase in smoking among the young population.

The report analyzes factors affecting lung cancer diagnosis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lung cancer diagnosis market in these regions.

The report also includes the profiles of key lung cancer diagnosis companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the lung cancer diagnosis market include, Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V., Oncimmune Holdings Plc, OncoCyte Corporation, QIAGEN, Quest Diagnostics, and Siemens Healthcare GmbH among others.